Patient characteristics
| . | AAT (n = 30) . | Control (n = 90) . |
|---|---|---|
| Years | 2018-2019 | 2015-2019 |
| Day high risk, n (%) | ||
| Day 7 | 19 (63) | 57 (63) |
| Day 14 | 11 (37) | 33 (37) |
| Median age (range), y | 51 (20-76) | 60 (19-76) |
| GVHD prophylaxis, n (%) | ||
| CNI/MTX | 14 (47) | 42 (47) |
| CNI/MMF | 0 (0) | 20 (22) |
| CNI/sirolimus | 15 (50) | 23 (26) |
| Cyclophosphamide based | 0 (0) | 4 (4) |
| Other | 1 (3) | 1 (1) |
| Donor type, n (%) | ||
| Related | 3 (10) | 9 (10) |
| Unrelated | 27 (90) | 81 (90) |
| HLA match, n (%) | ||
| Match | 29 (97) | 87 (97) |
| Mismatch | 1 (3) | 3 (3) |
| Graft source, n (%) | ||
| BM | 5 (17) | 11 (12) |
| PBSCs | 25 (83) | 79 (88) |
| Conditioning regimen Intensity, n (%) | ||
| Full | 11 (37) | 40 (44) |
| Reduced | 19 (63) | 50 (56) |
| ATG, n (%) | ||
| Yes | 6 (20) | 31 (34) |
| No | 24 (80) | 59 (66) |
| Indication for HCT, n (%) | ||
| Acute leukemia | 14 (47) | 39 (43) |
| Lymphoma | 1 (3) | 13 (15) |
| MDS/MPN | 13 (43) | 28 (31) |
| Other malignant | 0 (0) | 6 (7) |
| Other nonmalignant | 2 (7) | 4 (4) |
| Median day of GVHD diagnosis (range) | 30.5 (12-73) | 32 (10-162) |
| . | AAT (n = 30) . | Control (n = 90) . |
|---|---|---|
| Years | 2018-2019 | 2015-2019 |
| Day high risk, n (%) | ||
| Day 7 | 19 (63) | 57 (63) |
| Day 14 | 11 (37) | 33 (37) |
| Median age (range), y | 51 (20-76) | 60 (19-76) |
| GVHD prophylaxis, n (%) | ||
| CNI/MTX | 14 (47) | 42 (47) |
| CNI/MMF | 0 (0) | 20 (22) |
| CNI/sirolimus | 15 (50) | 23 (26) |
| Cyclophosphamide based | 0 (0) | 4 (4) |
| Other | 1 (3) | 1 (1) |
| Donor type, n (%) | ||
| Related | 3 (10) | 9 (10) |
| Unrelated | 27 (90) | 81 (90) |
| HLA match, n (%) | ||
| Match | 29 (97) | 87 (97) |
| Mismatch | 1 (3) | 3 (3) |
| Graft source, n (%) | ||
| BM | 5 (17) | 11 (12) |
| PBSCs | 25 (83) | 79 (88) |
| Conditioning regimen Intensity, n (%) | ||
| Full | 11 (37) | 40 (44) |
| Reduced | 19 (63) | 50 (56) |
| ATG, n (%) | ||
| Yes | 6 (20) | 31 (34) |
| No | 24 (80) | 59 (66) |
| Indication for HCT, n (%) | ||
| Acute leukemia | 14 (47) | 39 (43) |
| Lymphoma | 1 (3) | 13 (15) |
| MDS/MPN | 13 (43) | 28 (31) |
| Other malignant | 0 (0) | 6 (7) |
| Other nonmalignant | 2 (7) | 4 (4) |
| Median day of GVHD diagnosis (range) | 30.5 (12-73) | 32 (10-162) |
BM, bone marrow; CNI, calcineurin inhibitor; MDS/MPN, myelodysplastic syndromes/myeloproliferative neoplasms; MMF, mycophenolate; MTX, methotrexate; PBSCs, peripheral blood stem cells.